Is Jazz Pharmaceuticals (JAZZ) Still Attractive After 33% Share Price Gain This Year?

Simply Wall St.01-11

Wondering if Jazz Pharmaceuticals is still offering value at around US$161 a share, or if most of the opportunity has already been priced in? The stock is up 32.7% over the past year, even though it ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602534322?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-01-11 06:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602534322","market":"sg","top_or_hot":-1,"title":"Is Jazz Pharmaceuticals (JAZZ) Still Attractive After 33% Share Price Gain This Year?","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Jazz Pharmaceuticals is still offering value at around US$161 a share, or if most of the opportunity has already been priced in? The stock is up 32.7% over the past year, even though it ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/is-jazz-pharmaceuticals-jazz-still-attractive-after-33-share\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Jazz Pharmaceuticals (JAZZ) Still Attractive After 33% Share Price Gain This Year?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Jazz Pharmaceuticals (JAZZ) Still Attractive After 33% Share Price Gain This Year?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-11 06:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/is-jazz-pharmaceuticals-jazz-still-attractive-after-33-share><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Jazz Pharmaceuticals is still offering value at around US$161 a share, or if most of the opportunity has already been priced in? The stock is up 32.7% over the past year, even though it ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/is-jazz-pharmaceuticals-jazz-still-attractive-after-33-share\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2W23.USD","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/is-jazz-pharmaceuticals-jazz-still-attractive-after-33-share","article_id":"2602534322","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/is-jazz-pharmaceuticals-jazz-still-attractive-after-33-share","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602534322","pubTimestamp":1768083784,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Jazz Pharmaceuticals is still offering value at around US$161 a share, or if most of the opportunity has already been priced in?\nThe stock is up 32.7% over the past year, even though it has seen a 6.9% decline over the last week and a 2.3% decline over the past month.\nRecent attention on Jazz Pharmaceuticals has centered on its position in pharmaceuticals and biotech, with investors weighing the company against sector peers and sentiment around the broader drug development...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","JAZZ":"爵士制药","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4007":"制药","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"Jazz Pharmaceuticals(JAZZ)今年股价上涨33%后仍有吸引力吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1.5,"DCF":1},"content_text":"Wondering if Jazz Pharmaceuticals is still offering value at around US$161 a share, or if most of the opportunity has already been priced in? The stock is up 32.7% over the past year, even though it has seen a 6.9% decline over the last week and a 2.3% decline over the past month. Recent attention on Jazz Pharmaceuticals has centered on its position in pharmaceuticals and biotech, with investors weighing the company against sector peers and sentiment around the broader drug development space. This backdrop helps explain why the share price has moved in both directions over shorter time frames, while still sitting higher over the last year. On our valuation checks Jazz Pharmaceuticals scores a full 6 out of 6 for being assessed as undervalued. Next we will look at how different valuation methods arrive at that view and why there may be an even better way to think about value by the end of this article.  Jazz Pharmaceuticals delivered 32.7% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. AdvertisementApproach 1: Jazz Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and then discounting those back to a present value. For Jazz Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $1.18b. Analysts provide detailed free cash flow estimates for the next few years, and beyond that, Simply Wall St extrapolates cash flows out to 2035 based on those inputs. Under this framework, projected free cash flow in 2030 is $2.10b. The series of discounted cash flows across the coming decade is then summed to arrive at an estimated intrinsic value of about $772.86 per share. Against a current share price around $161, the model suggests Jazz Pharmaceuticals trades at a 79.2% discount to this DCF estimate, which implies the shares are assessed as significantly undervalued on these cash flow assumptions. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Jazz Pharmaceuticals is undervalued by 79.2%. Track this in your watchlist or portfolio, or discover 877 more undervalued stocks based on cash flows. JAZZ Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Jazz Pharmaceuticals. Approach 2: Jazz Pharmaceuticals Price vs Sales For companies that are already generating meaningful revenue, the P/S ratio can be a useful cross check because it compares what the market is paying for each dollar of sales rather than relying on earnings, which can be affected by accounting items and one off charges. In general, higher growth expectations and lower perceived risk tend to justify a higher “normal” or “fair” trading multiple, while slower growth or higher risk usually point to a lower ratio being reasonable. Jazz Pharmaceuticals currently trades on a P/S of 2.35x. That sits below the Pharmaceuticals industry average P/S of 4.30x and also below the peer group average of 3.66x. Simply Wall St’s Fair Ratio for Jazz Pharmaceuticals is 7.08x, which reflects a proprietary view of what P/S might be appropriate once factors such as earnings growth, profit margins, industry, market cap and risk profile are taken into account. The Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for company specific traits rather than assuming all firms in the sector deserve similar multiples. Comparing the Fair Ratio of 7.08x with the current 2.35x suggests Jazz Pharmaceuticals is assessed as undervalued on this P/S framework. Result: UNDERVALUED NasdaqGS:JAZZ P/S Ratio as at Jan 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1441 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Jazz Pharmaceuticals Narrative Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St's Community page you can use Narratives, where you set out your story for Jazz Pharmaceuticals by linking your view on its future revenue, earnings and margins to a financial forecast and fair value. You can then compare that fair value with the current price to decide whether you think the stock looks attractive or not. The Narrative updates automatically as new news or earnings arrive. One investor might build a more optimistic Jazz view around the higher US$230 analyst fair value and stronger oncology growth assumptions, while another might lean toward the more cautious US$147 fair value and slower uptake assumptions. Both can transparently see how their story feeds into their numbers. Do you think there's more to the story for Jazz Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGS:JAZZ 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602534322","isCrawlerRequest":true}